Research focus: novel approach to advance treatment of KRAS-driven non-small cell lung cancer based on ERK5 and FAK inhibition
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Research focus: novel approach to advance treatment of KRAS-driven non-small cell lung cancer based on ERK5 and FAK inhibition
-
Narrado por:
-
De:
Acerca de esta escucha
We speak with Dr. Georgia Konstantinidou and Dr. Chiara Pozzato from University of Bern about their recent pre-clinical research investigating a new potential treatment approach for KRAS driven cancers. The conversation explores the role of FAK signalling in KRAS driven NSCLC and potential approaches to bypass drug resistance against FAK inhibitors from the molecular mechanisms involved to the impact of their study for the wider cancer research community.
This study has been published in EMBO Molecular Medicine and was included in the EACR's Highlights in Cancer Research, a summary of the most interesting and impactful recent papers in cancer research.
🔗 Read more about the publication: https://magazine.eacr.org/highlights-in-cancer-research-december-2024/7/
🔗 Access transcripts for all our episodes at magazine.eacr.org/podcast